Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial.
EFTISARC-NEO is evaluating Immutep's investigative LAG-3 immunotherapy eftilagimod alpha (efti) in combination with radiotherapy plus MSD's KEYTRUDA (pembrolizumab) in the neo-adjuvant setting for patients with resectable soft tissue sarcoma (STS).
The Phase 2 trial conducted by the Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, the national reference centre for STS in Poland, has reached its enrolment target of 40 patients.
The company has previously announced positive data from EFTISARC-NEO was presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting in November 2024.
Among 21 patients available for primary endpoint assessment, the triple combination achieved a greater than three-fold increase in tumour hyalinisation/fibrosis at the time of surgical resection compared to a historical median of 15 per cent from radiotherapy alone.
Immutep said this is an early surrogate endpoint at the time of surgery as tumour hyalinization/fibrosis has been associated with improved survival for STS patients.